Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
European Journal of Heart Failure|August 4, 2023
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSEJoão Pedro Ferreira, Jonathan P Blatchford, John R Teerlink, et al.
Circulation. Heart Failure|May 19, 2023
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF TrialsMichael E Nassif, Sheryl L Windsor, Kensey Gosch, et al.
Journal of the American College of Cardiology|November 12, 2021
In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection FractionVishal N Rao, Evan Murray, Javed Butler, et al.
JACC. Heart Failure|June 10, 2019
Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HFMerrill Thomas, Yevgeniy Khariton, Gregg C Fonarow, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
European Heart Journal|October 21, 2025
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialMartin S Maron, Juan Ramon Gimeno, Josef Veselka, et al.
The American Journal of Cardiology|April 19, 2026
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract GradientsJosef Veselka, Ramon Gimeno, Theodore P Abraham, et al.
Circulation|May 23, 2022
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HFSenthil Selvaraj, Zhuxuan Fu, Philip Jones, et al.
JACC. Heart Failure|April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyAhmad Masri, Martin S Maron, Theodore P Abraham, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
Pageof 9